Evidence map›Paper›PMID 35783669›Full record

ArticleSAGE open medical case reports2022

Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report.

Maroun Bou Zerdan, Ramzi Hamouche, Youssef Bouferraa, Camil Chouairy, Dany Gholam

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Maroun Bou ZerdanDepartment of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.ORCID https://orcid.org/0000-0002-9229-3079
Ramzi HamoucheYale-Waterbury Internal Medicine Residency Program, Waterbury, CT, USA.
Youssef BouferraaDepartment of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Camil ChouairyDepartment of Pathology, Saint George Hospital University Medical Center, Beirut, Lebanon.
Dany GholamDepartment of Hematology and Oncology, Saint George Hospital University Medical Center (SGHUMC), Beirut, Lebanon.
Saint George Hospital · LBCleveland Clinic · USSUNY Upstate Medical University · USWaterbury Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignancies with unknown primaries contribute to a small yet significant percentage of overall tumors. Neuroendocrine carcinomas, a rare disease with a poor prognosis, have been known to present as an unknown primary. Treatment consists of cytotoxic chemotherapy but given the latter's high toxicity profile new treatment options are being explored. In this case report, we describe a case of a patient with poorly differentiated neuroendocrine carcinoma of unknown primary treated with compassionate oral everolimus after his refusal of intravenous chemotherapy.

Indexed as

Everolimushematologyoncologypoorly differentiated neuroendocrine carcinoma

Identifiers

PMID35783669
PMCPMC9247284
OpenAlexW4285226063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.